PATENT CLAIM ANALYSIS

Application Number: 15928123
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "085600"]

Abstract:
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

Claim (Index 15):
The method of  claim 1 , wherein Cladribine is administered from 4 to 7 days per month during the induction period.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.17241
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12301083', '11722018', '12766173', '09904263', '15032919']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7592070035451602
- 35 USC 102 Novelty (BERT): 0.5687810211447146
- Combined Prediction Score: 0.7401644053051156
- Mean Citation Score: 317.2390000000001
- Max Citation Score: 446.3266
- Similarity Product: 416.38937002106906

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test